Kidney cancer in 2024: health equity, ‘practice changing’ regimens and more
Click Here to Manage Email Alerts
In 2024, the treatment landscape for kidney cancer evolved, with new breakthroughs in combination therapies, new challenges and an emphasis on addressing disparities in care.
This review explores five key updates, offering an overview of where renal cell carcinoma research, treatment and health equity efforts stand as a new year approaches.
1. Combining gut microbiome manipulation with immunotherapy and tyrosine kinase inhibitor therapy conveyed clinical benefit for patients with metastatic renal cell carcinoma. Read more.
2. Researchers at Brigham and Women’s Hospital developed a tool that predicts risks for moderate to severe kidney injury after treatment with the chemotherapy drug cisplatin. Read more.
3. Immunotherapy utilization for treatment of advanced kidney or bladder cancers varied by patients’ race or socioeconomic status. Read more.
4. Pembrolizumab (Keytruda, Merck) after surgery shows ‘practice changing’ survival benefit for kidney cancer. Read more.
5. Subcutaneous nivolumab (Opdivo, Bristol Myers Squibb) can reduce burdens on the health care system and patients with pretreated advanced or metastatic clear renal cell carcinoma compared with its IV formulation. Read more.
Collapse
Healio Coverage
Click Here to Manage Email Alerts